Three things to know:
1. The test will analyze 23andMe customers’ DNA for two genetic variants that influence MUTYH-associated polyposis, a rare condition linked with an increased risk of colorectal cancer.
2. Hereditary colorectal cancers make up just 5 percent of all colorectal cancer cases. 23andMe’s new test doesn’t look for genetic variants associated with Lynch syndrome, the most common form of inherited colorectal cancer.
3. This marks 23andMe’s second FDA-cleared test that assesses cancer risk. In March 2018, 23andMe began offering a test that reports on mutations in two genes, BRCA1 and BRCA2, which are associated with an increased risk of breast cancer.
More articles on supply chain:
Verily’s smartwatch gets FDA clearance for EKG: 4 things to know
Intalere taps Medline for lab distribution services
The first generic of Sabril, a heart device for premature babies, and 2 more FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.